A lifetime registry and imaging database for people with heart, kidney, and metabolic conditions

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-center observational registry at the First Affiliated Hospital of Fujian Medical University will combine retrospective inpatient records with prospective annual follow-up for up to five years. It will link multi-source hospital data—including diagnoses, laboratory tests, medications, ECG, echocardiography, vascular function tests, carotid and abdominal ultrasound, bone density, coronary CTA and post-processing metrics, and clinical outcomes—using a patient-centered master index. The database will support standardized CKM phenotyping, event adjudication, and repeat-assessment tracking, with a primary outcome of time-to-first cardiorenal composite endpoint. Monthly passive data updates and active yearly follow-up aim to generate real-world evidence for risk stratification and management of cardio-renal-metabolic patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 18 years or older.
* Inpatient record available at the First Affiliated Hospital of Fujian Medical University with retrievable identifiers for data linkage.
* Cardiovascular disease, kidney disease, metabolic disease, or key examination/laboratory information supporting CKM phenotyping.
* Willingness to participate and provision of written informed consent.
* Ability to complete baseline assessment and follow-up.
* Full civil capacity and ability to understand study information.

Exclusion Criteria:

* Refusal to provide written informed consent.
* Severe psychiatric disease or cognitive impairment precluding participation.
* End-stage disease with expected survival less than 1 year.
* Long-term absence more than 6 months preventing reliable follow-up.
* Participation in another clinical study that may interfere with endpoint adjudication.
* Missing key fields preventing linkage of examinations, imaging, and outcomes.

Where it's running

• The First Affiliated Hospital of Fujian Medical University
  Fuzhou, Fujian, China Recruiting

Study contacts

• Principal investigator: Dajun Chai — First Affiliated Hospital of Fujian Medical University
• Study coordinator: Dajun Chai
• Email: dajunchai-fy@fjmu.edu.cn
• Phone: 008659187981637

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combining genetics, blood, urine, and stool data to predict complications of metabolic syndrome

  The team will try combining genetic, blood, urine, and stool data to see if patterns predict complications in adults with or without metabolic syndrome.

  Recruiting Chang Gung Memorial Hospital · Taoyuan · NCT07248371

• Heart, kidney, and metabolic health in Shanghai community residents

  This follow-up will track people from the STONE cohort to see if changes in metabolic risk factors over time relate to heart and kidney outcomes.

  Recruiting Shanghai Changzheng Hospital · Shanghai, Shanghai Municipality · NCT07043166

• Observational look at how Kremezin works in adults with advanced chronic kidney disease

  This study tests whether Kremezin helps adults with advanced kidney disease when used as part of routine care, by tracking safety and kidney function over up to 48 weeks.

  Recruiting HK inno.N Corporation · Seoul · NCT07930169

• Tailored digital support to cut sedentary time in long-term cardiac rehab

  In adults in a long-term cardiac rehabilitation program, this study tests whether a personalized behavioural program with digital tools can reduce daily sitting time.

  Recruiting University of Lisbon · Lisbon, Lisbon District · NCT07910812

• Registering medical data and care outcomes for ALS, SMA, and other motor disorders

  This registry slowly collects routine-care information from adults with ALS, SMA, or other motor disorders to see how they’re treated and how care affects outcomes.

  Recruiting Ambulanzpartner Soziotechnologie APST GmbH · Berlin, State of Berlin · NCT07900672

• Kidney and Heart Health in Adults with Type 2 Diabetes and CKD Treated with Semaglutide in China

  This study tests whether semaglutide injections help kidney and heart health in adults with type 2 diabetes and chronic kidney disease.

  Recruiting Phase 4 Novo Nordisk A/S · Fuyang, Anhui and 25 other locations · NCT07900438

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.